Company intelligence / Profile preview
Mediar Therapeutics
Cambridge, Massachusetts, USAmediartx.com ↗
- Ownership
- Private
- Employees
- ~27
- Development stage
- Other
01
Overview
Currently conducting Phase 1 trials for two lead candidates: MTX-463 (targeting WISP1) and MTX-474 (targeting EphrinB2). MTX-463 has received orphan drug and fast track designations from the FDA for IPF. Phase 1 study for MTX-463 is enrolling ahead of schedule with most cohorts dosed as of August 2024, with completion expected by the end of 2024. The company is planning Phase 2 trials in 2025.
- Therapeutic areas
- PulmonologyRare DiseasesRheumatology
- Modalities
- Antibodies (monoclonal antibodies)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on Mediar Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mediar Therapeutics.